Savara Inc (NASDAQ:SVRA) Receives $8.83 Average PT from Brokerages

Savara Inc (NASDAQ:SVRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $8.83.

Several research firms recently weighed in on SVRA. JMP Securities restated a "market outperform" rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company initiated coverage on Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $6.00 price objective on shares of Savara in a report on Friday, March 28th.

Savara Stock Down 2.0 %

Shares of SVRA stock traded down $0.06 during trading hours on Friday, reaching $2.87. The company had a trading volume of 45,634 shares, compared to its average volume of 1,017,422. The company has a market cap of $495.46 million, a price-to-earnings ratio of -6.67 and a beta of 0.52. The business has a fifty day simple moving average of $2.73 and a 200-day simple moving average of $3.11. Savara has a 12 month low of $2.26 and a 12 month high of $5.31. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. On average, research analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

Several institutional investors and hedge funds have recently added to or reduced their stakes in SVRA. Vestal Point Capital LP grew its holdings in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after purchasing an additional 2,685,000 shares during the period. Rosalind Advisors Inc. purchased a new stake in shares of Savara in the fourth quarter worth $8,151,000. Nantahala Capital Management LLC boosted its stake in Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock worth $23,103,000 after purchasing an additional 2,344,308 shares in the last quarter. Emerald Advisers LLC bought a new stake in Savara during the 4th quarter valued at about $7,161,000. Finally, Farallon Capital Management LLC lifted its stake in shares of Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after buying an additional 2,275,000 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.